Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 2/3

Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia

NCT07841470 · tracked via the Priya Life Science USA tracker
Sponsor
Price Vision Group
Phase
Phase 2/3
Started
2025-10-01
Last updated
2026-09-25

Condition(s) studied

KeratoconusCorneal Ectasia

Investigational drug(s) / intervention(s)

Riboflavin 0.1% ophthalmic solution and pulsed lightRiboflavin 0.1% ophthalmic solution and non-pulsed light

Riboflavin 0.1% ophthalmic solution and pulsed light: Use of riboflavin 0.1% eye drops and pulsed 18 milliwatt/cm2 ultraviolet A light for 10 minutes

Riboflavin 0.1% ophthalmic solution and non-pulsed light: Use of riboflavin 0.1% eye drops and non-pulsed 9 milliwatt/cm2 ultraviolet A light for 10 minutes

Study summary

This randomized study compares 2 variations of corneal crosslinking for treatment of keratoconus or corneal ectasia.

Eligibility

Sex
ALL
Min age
10 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of keratoconus or corneal ectasia * Provision of written informed consent Exclusion Criteria: * Previous ocular condition in the study eye that may predispose for future complications including history of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.) * Clinically significant corneal scarring in the proposed treatment zone * History of chemical injury or delayed epithelial healing in the study eye * Known sensitivity to study medication * A current condition, including clinically significant dry eyes or use of medications know to induce dry eye symptoms, that, in the treating physician's opinion, would interfere with or prolong epithelial healing * Pregnancy (including plan to become pregnant) or lactation during the course of the study

Primary outcome measure(s)

  • Change in maximum keratometry — 6 months
    assessed with corneal tomography

Trial sites (1)

FacilityCityRegionStatus
Price Vision Group Indianapolis Indiana Recruiting

More Price Vision Group trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07841470 on ClinicalTrials.gov ↗ ← All trials in the USA